Introduction
Voltage-gated sodium channels (Na v ) are responsible for the normal electrical activity of excitable cells, including neurons, skeletal muscle, and cardiomyocytes ( Burgess et al., 1995 ; Cannon, 1996 ; Escayg et al., 2000 ; Keating and Sanguinetti, 2001 ; Lossin et al., 2002 ; Papadatos et al., 2002 ; Yu et al., 2005 ) . Na v 1.5 (encoded by SCN5A ) is the principal Na v channel in vertebrate heart. Na v 1.5-dependent activity underlies the rapid upstroke of the cardiac action potential ( Keating and Sanguinetti, 2001 ) . Na v 1.5 activity depends on precise biophysical properties that regulate inward Na + current in response to cardiomyocyte membrane potential. Human SCN5A variants that affect biophysical properties of Na v 1.5 are associated with several potentially fatal arrhythmias, including type 3 long QT syndrome (LQT3; variants increase inward Na + current) and Brugada Syndrome (variants reduce inward Na + current; Priori, 2004 ; Shah et al., 2005 ) . In addition to normal biophysical properties, Na v 1.5 activity requires proper localization at specialized cardiomyocyte membrane domains. In the vertebrate heart, Na v 1.5 is primarily concentrated at the cardiomyocyte intercalated disc ( Kucera et al., 2002 ; Maier et al., 2002 ; Mohler et al., 2004b ) . However, Na v 1.5 localization at the peripheral sarcolemma and T tubules has also been described previously ( Cohen, 1996 ; Scriven et al., 2000 Scriven et al., , 2002 Kucera et al., 2002 ) . The molecular mechanisms underlying the targeting and retention of Na v 1.5 in cardiac tissue are unknown. Over the past decade, several potential Na v 1.5 intermolecular interactions have been hypothesized to regulate Na v 1.5 membrane traffi cking, stability, and removal ( Herfst et al., 2004; Abriel and Kass, 2005 ) . However, the roles for these protein interactions in the context of a cardiomyocyte are unclear.
Ankyrin-G is an adaptor protein required for the targeting of diverse membrane proteins in the central nervous system ( Mohler and Bennett, 2005b ) . Specifi cally, ankyrin-G is required for the targeting of Na v channel isoforms (Na v 1.2 and Na v 1.6) to specialized excitable membrane domains (axon initial segments and nodes of Ranvier) in Purkinje and granule cell neurons ( Zhou et al., 1998; Jenkins and Bennett, 2001 ; Garrido et al., 2003 ; Lemaillet et al., 2003 ) . Mice lacking ankyrin-G expression in the cerebellum display a loss of Na v channel targeting, abnormal neuronal action potentials, and ataxia ( Zhou et al., 1998; Jenkins and Bennett, 2001 ) . In 2003, two independent groups identifi ed a small binding motif in the Na v 1.2 DII -DIII cytoplasmic loop required for ankyrin-G association ( Garrido et al., 2003 ; Lemaillet et al., 2003 ) .
Our group recently identifi ed 190-kD ankyrin-G expression in the heart ( Mohler et al., 2004b ) . Like Na v 1.5, ankyrin-G is expressed at the intercalated disc and transverse tubules and V oltage-gated Na v channels are required for normal electrical activity in neurons, skeletal muscle, and cardiomyocytes. In the heart, Na v 1.5 is the predominant Na v channel, and Na v 1.5-dependent activity regulates rapid upstroke of the cardiac action potential. Na v 1.5 activity requires precise localization at specialized cardiomyocyte membrane domains. However, the molecular mechanisms underlying Na v channel traffi cking in the heart are unknown. In this paper, we demonstrate that ankyrin-G is required for Na v 1.5 targeting in the heart.
Cardiomyocytes with reduced ankyrin-G display reduced Na v 1.5 expression, abnormal Na v 1.5 membrane targeting, and reduced Na + channel current density. We defi ne the structural requirements on ankyrin-G for Na v 1.5 interactions and demonstrate that loss of Na v 1.5 targeting is caused by the loss of direct Na v 1.5 -ankyrin-G interaction. These data are the fi rst report of a cellular pathway required for Na v channel traffi cking in the heart and suggest that ankyrin-G is critical for cardiac depolarization and Na v channel organization in multiple excitable tissues.
Voltage-gated Na v channel targeting in the heart requires an ankyrin-G -dependent cellular pathway
Rat cardiomyocytes lacking a full complement of ankyrin-G expression were used to test the role of ankyrin-G for Na v 1.5 expression. As shown in Fig. 1 , viral transduction of ankyrin-G associates with Na v 1.5 in coimmunoprecipitation and in vitro binding experiments ( Mohler et al., 2004b ) . The nine -amino acid ankyrin-binding sequence identifi ed in Na v 1.2 ( Garrido et al., 2003 ; Lemaillet et al., 2003 ) is present in Na v 1.5 and is required for Na v 1.5 -ankyrin-G interaction ( Mohler et al., 2004b ) . A human Brugada Syndrome SCN5A variant in the Nav1.5 ankyrin-Gbinding motif (E1053K) abolishes ankyrin-G -Na v 1.5 interaction, and this Na v channel mutant is not effi ciently targeted to cardiomyocyte membranes ( Mohler et al., 2004b ) . Although largely circumstantial, these data support a potential role for an ankyrin-Gdependent pathway in Na v 1.5 targeting to excitable membrane domains in the heart.
In this study, we report new data that conclusively links ankyrin-G activity and Na v 1.5 membrane expression and localization in cardiomyocytes. Using viral-mediated small hairpin RNA (shRNA) transfer into primary cardiomyocytes, we demonstrate that a full complement of ankyrin-G expression is required for Na v 1.5 expression and membrane localization. Specifi cally, reduced ankyrin-G expression decreases (1) total cellular Na v 1.5 expression, (2) effi cient membrane localization, and (3) total Na + membrane current. We also demonstrate that although ankyrin-G is required for normal Na v 1.5 membrane expression, reduced ankyrin-G expression does not affect Na v 1.5 channel kinetics. Finally, we report the structural requirements for direct ankyrin-G -Na v 1.5 interactions and show that direct intermolecular interaction between these two molecules is required for effi cient channel membrane localization. Together, these data identify the fi rst clear cellular pathway for Na v channel traffi cking in the heart. ankyrin-G with the site of shRNA target. Rat, mouse, and human shRNA nucleotide target sequences. Note that the human 190-kD ankyrin-G target sequence has three unique nucleotides in wobble base positions (asterisks) that render this target sequence resistant to the rat shRNA. (B) The 21-nucleotide target sequence (sense) is separated by a short loop spacer sequence followed by 21 nucleotides that form the reverse complement of the target sequence. (C) Rat and human species -specifi c shRNAs reduce 190-kD ankyrin-G expression. Rat myocytes or human HEK293 cells were transduced with control virus, rat ankyrin-G shRNA, or human ankyrin-G shRNA. Equal quantities of protein were analyzed by immunoblotting using affi nitypurifi ed ankyrin-G Ig or an antibody to an unrelated protein, NHERF1 (loading control). Note that the rat-specifi c ankyrin-G shRNA effectively reduces the expression of 190-kD ankyrin-G in rat cardiomyocytes. Moreover, the expression of 190-kD ankyrin-G is reduced in HEK293 cells transduced with human-specifi c ankyrin-G shRNA. (D) 190-kD ankyrin-G protein levels from whole cell lysates of rat cardiomyocytes transduced with control virus, humanspecifi c ankyrin-G shRNA virus (hAnkG shRNA), or rat-specifi c ankyrin-G shRNA virus (rAnkG shRNA) were analyzed by immunoblotting and quantitated. Numbers represent the mean ± SD (error bars) from four independent experiments. *, P < 0.05.
shRNA signifi cantly reduces ankyrin-G expression (transduction effi ciency of 80 -95% based on YFP fl uorescence ; Fig. 2 ). Moreover, a striking reduction in Na v 1.5 protein levels was observed in the identical cell lysates from rat-specifi c ankyrin-G shRNA virally transduced myocytes ( Fig. 2 ) . This reduction was specifi c to Na v 1.5, as expression differences in cardiomyocyte membrane -associated proteins, including NHERF1, connexin43, ankyrin-B, Ca v 1.2 ( Fig. 2 ) , SERCA2, Na/K ATPase, or Na/Ca exchanger (not depicted), were not observed.
The role of ankyrin-G on single cardiomyocyte Na v 1.5 expression was examined using immunofl uorescence and confocal microscopy. In agreement with immunoblot data of cardiomyocyte populations ( Fig. 2 ) , reduced ankyrin-G expression resulted in a dramatic loss of Na v 1.5 cellular expression ( Fig. 3 C ) compared with nontransduced ( Fig. 3 A ) , YFP-transduced ( Fig. 3 B ) , and human-specifi c ankyrin-G shRNA -transduced myocytes ( Fig. 3 D ) . Specifi cally, Na v 1.5 expression appeared to only remain in the perinuclear region of cardiomyocytes lacking ankyrin-G expression ( Fig. 3 C ) . Loss of protein localization was limited to Na v 1.5, as cardiomyocytes transduced with ankyrin-G shRNA displayed no difference in the expression or localization of either Ca v 1.2 or Na/Ca exchanger (Fig. S1 , available at http:// www.jcb.org/cgi/content/full/jcb.200710107/DC1).
Ankyrin-B is not required for Na v 1.5 expression in cardiomyocytes
Ankyrin-B (encoded by ANK2 ) is required for the membrane targeting of Na/Ca exchanger, InsP 3 receptor, and Na/K ATPase in cardiomyocytes ( Mohler et al., 2002 ( Mohler et al., , 2003 ( Mohler et al., , 2005 . Ankyrin-B and -G are structurally similar and share binding activity for protein partners, including ␤ -spectrin and Na/K ATPase ( Devarajan et al., 1994 ; Kizhatil and Bennett, 2004 ; Mohler et al., 2004d Mohler et al., , 2005 Kizhatil et al., 2007 ) . We used primary cardiomyocytes from ankyrin-B -null mice to test whether ankyrin-B expression is necessary for Na v 1.5 membrane expression. Confocal analyses of wild-type, ankyrin-B +/ Ϫ , and ankyrin-B -null cardiomyocytes revealed no difference in Na v 1.5 immunolocalization ( Fig. 4 , A -C ). Therefore, even in myocytes completely devoid of ankyrin-B expression, Na v 1.5 was normally expressed and properly localized. These results demonstrate that ankyrin-G (not ankyrin-B) is the physiological binding partner for Na v 1.5 in the heart. Ankyrin-G is required for normal Na v 1.5-dependent Na + current in cardiomyocytes
We made electrophysiological measurements to determine whether reduced ankyrin-G expression signifi cantly affects Na v channel membrane current density in primary cardiomyocytes ( Fig. 5 ) . Wild-type rat cardiomyocytes and cardiomyocytes transduced with human-or rat-specifi c ankyrin-G shRNA virus were analyzed for sodium current using whole-cell patch clamp (see Fig. 5 D [inset] for protocol). Virally transduced cardiomyocytes were selected for electrophysiological measurements on the basis of positive YFP fl uorescence. Cardiomyocytes infected with human-specifi c ankyrin-G shRNA virus displayed no change in peak Na + current compared with control (nontransduced) myocytes (note the current traces in Fig. 5 [A and B ] and the current-voltage relationship in Fig. 5 D ) . In contrast, myocytes Figure 2 . Na v 1.5 expression is reduced in rat myocytes with reduced ankyrin-G expression. Neonatal cardiomyocytes were transduced with rat-specifi c ankyrin-G shRNA virus. After 22 h, myocytes were collected, and whole cell lysates were generated. Equal protein concentrations were analyzed by immunoblot using affi nity-purifi ed ankyrin-G Ig and Na v 1.5-specifi c antibody. In parallel, blots were probed with an unrelated Ig to ensure equal protein loading (NHERF1). Note that loss of 190-kD ankyrin-G expression in myocytes transduced with rat-specifi c ankyrin-G shRNA was paralleled by a signifi cant reduction in Na v 1.5 expression. Reduced ankyrin-G expression did not affect the expression of ankyrin-B, connexin43, or Ca v 1.2. Molecular masses are expressed in kilodaltons.
transduced with rat-specifi c ankyrin-G shRNA virus displayed striking decreases in peak Na + current density (note the traces in Fig. 5 C ; currents normalized for cell capacitance). In fact, several transduced cells that completely lacked detectable Na + current (data not included in statistical analyses for Figs. 5 and 6; see Materials and methods) were observed. These functional data strongly support a role for ankyrin-G in Na v 1.5 membrane surface targeting in cardiomyocytes. , rat-specifi c ankyrin-G shRNA virus (C), or human-specifi c ankyrin-G shRNA virus (D) were immunolabeled with ankyrin-G and Na v 1.5-specifi c antibodies and imaged using identical confocal settings. Viral transduction was assessed by the presence of YFP fl uorescence (pseudocolored in blue in B -D for clarity). Note that only myocytes infected with rat-specifi c ankyrin-G shRNA virus displayed reduced ankyrin-G expression. These myocytes consistently displayed a decreased expression of Na v 1.5. In fact, Na v 1.5 expression in myocytes with reduced ankyrin-G expression (arrowheads in C) was limited to the perinuclear region (arrows in C). Bars, 10 m.
To determine the specifi city of the ankyrin-G -based cellular pathway for ion channel membrane targeting in cardiomyocytes, we evaluated the effect of reduced ankyrin-G expression on a second critical cardiomyocyte membrane current. Ca v 1.2-dependent calcium current (I Ca ) is required for normal cardiac excitability, and human Ca v 1.2 gene variants are associated with ventricular arrhythmia ( Splawski et al., 2004 ) . As expected, myocytes with reduced ankyrin-G expression displayed signifi cant reduction in peak Na + observed in wild-type cardiomyocytes versus cardiomyocytes with reduced ankyrin-G expression ( Fig. 6 ). These data demonstrate that in the physiological context of a cardiomyocyte, normal Na v channel inactivation does not require ankyrin-G. Surprisingly, inactivation of wild-type cardiomyocyte Na v 1.5 is independent of physiological localization. Thus, localization controls current density but not Na v 1.5 inactivation. These data strongly demonstrate the critical nature of studying ankyrin biology in the appropriate physiological context.
Direct interaction between ankyrin-G and

Na v 1.5 requires ANK repeat 14 -15
␤ -hairpin loop tips
We identifi ed the structural requirements on ankyrin-G for direct Na v 1.5 interaction using a series of ankyrin-G ANK repeat mutants ( Fig. 7 , A -C ). These mutants were created based on the identifi cation of exposed, highly accessible residues on the ␤ -hairpin loop tips of the ankyrin-R membrane -binding domain (repeats 13 -24) crystal structure ( Michaely et al., 2002 ) as well as the identifi cation of membrane -protein binding sites at these sites in ankyrin-B ( Mohler et al., 2004a; Cunha et al., 2007 ) . Specifi cally, each of the 24 consecutive ANK repeats of an ankyrin membrane -binding domain fold as antiparallel pairs of ␣ helices connected by a ␤ -hairpin loop. The large number of consecutive ANK repeats come together to form a super helix that surrounds a large central cavity ( Michaely et al., 2002 ) . Thus, these variable ␤ -hairpin loops are highly accessible to the solvent for potential protein interactions ( Fig. 7 C ) . This strategy has been successfully used to map the binding sites on ankyrin-B for Na/Ca exchanger and InsP 3 receptor ( Mohler et al., 2004a; Cunha et al., 2007 ) . current amplitude ( Fig. 5, F and G ) . However, these identical myocytes displayed peak calcium current (I Ca ) measurements that were unchanged from those observed in control (nontransduced) or human-specifi c ankyrin-G shRNA virally transduced cardiomyocytes (see Materials and methods for protocol details ; Fig. 5 , F and G ). These data (combined with Na v 1.5/Ca v 1.2 immuno blot and immunostaining data in Figs. 2 -4 and S1) establish that the cardiac ankyrin-G -targeting pathway is specifi c for Na v 1.5 channels and that loss of Na v 1.5 membrane expression in ankyrin-Gdefi cient cells is not simply the result of the general impairment of default myocyte membrane biogenesis/traffi cking pathways.
Na v 1.5 channel inactivation is unaffected in cardiomyocytes with reduced ankyrin-G expression
Human Na v 1.5 Brugada Syndrome variant E1053K, which lacks ankyrin-G -binding activity, is not effi ciently targeted to the cardiomyocyte intercalated disc ( Mohler et al., 2004b ) . However, when introduced into heterologous HEK293 cells, this mutant channel is present at the plasma membrane but displays abnormalities in Na v 1.5 inactivation ( Mohler et al., 2004b ) . Furthermore, similar data examining Na v 1.2 biophysical properties in TsA201 cells support the concept that ankyrin-G could potentially regulate the biophysical properties of Na v channels in heterologous cells ( Shirahata et al., 2006 ) . These studies did not determine whether the inactivation of wild-type Na v 1.5 channels requires correct localization through ankyrin-G. Therefore, we tested whether primary cardiomyocytes with reduced ankyrin-G expression displayed abnormalities in Na v channel inactivation. No signifi cant difference in Na v 1.5 channel inactivation was Nontransduced cardiomyocytes (control) and cardiomyocytes transduced with human-(hAnkG) or rat-specifi c (rAnkG) shRNA virus were analyzed for Na v 1.5 current. (A -C) Whole-cell patch clamp sodium current traces elicited control (A; 17 pF), human ankyrin-G -specifi c shRNA -transduced cells (B; 18 pF), and rat-specifi c ankyrin-G shRNA -transduced cells (C; 16.8 pF). All cardiomyocytes displayed similar cell capacitance, and all traces are normalized for cell capacitance. (D) Mean and normalized current-voltage relationship for neonatal rat ventricular cardiomyocytes treated with control virus (black squares; n = 10), human ankyrin-G shRNA virus (gray circles; n = 10), and rat ankyrin-G shRNA virus (white squares; n = 10). (E) Normalized maximum sodium current amplitude in myocytes treated with control (black bar) and rat-(white bar) and human (gray bar)-specifi c ankyrin-G shRNA virus. *, P < 0.05. (F and G) Reduced ankyrin-G expression specifi cally affects cardiomyocyte sodium current. (F) Amplitude of Na + and Ca 2+ current in nontransduced (control) and rat neonatal cardiomyocytes transduced with ankyrin-G species-specifi c shRNA viruses. Currents are elicited with the protocol shown in the inset (see Materials and methods for details). Left panels depict Na + and Ca 2+ current in cardiomyocytes treated with control or human ankyrin-G -specifi c shRNA virus (hAnkG shRNA). Right panels display the signifi cant decrease in I Na , but not I Ca , in cardiomyocytes transduced with rat-specifi c ankyrin-G shRNA virus (rAnkG shRNA). All traces are normalized for cell capacitance. (G) Reduced ankyrin-G expression leads to reduced I Na but does not affect cardiomyocyte I Ca . (E and G) Data are plotted as mean ± SEM (error bars; n = 10). Statistical difference was analyzed by analysis of variance.
Mutant plasmids were completely sequenced to verify that no additional mutations were introduced during PCR amplifi cation. Wild-type ankyrin-G and each GFP ankyrin-G mutant were expressed in HEK293 cells. Expressed proteins were immunopurified from the detergent-soluble fraction of the cells using immobilized affi nity-purifi ed GFP Ig and were incubated with purifi ed His-tagged Na v 1.5 DII -DIII cytoplasmic loop (site for ankyrin-G association on Na v 1.5; Mohler et al., 2004b ) . The quantity of pure Na v 1.5 DII -DIII bound to each mutant was determined by immunoblotting using a His tag Ig. Using similar methods, the relative level of GFP -ankyrin-G mutant expression for each data point was determined. The amount of Na v 1.5 His-tagged DII -DIII bound to each ankyrin-G mutant was corrected for relative GFP -ankyrin-G expression in each experimental sample.
Although the majority of ankyrin-G mutants associated with Na v 1.5 His-tagged DII -DIII at levels similar to wild-type GFP -ankyrin-G, there was a signifi cant reduction in DII -DIII binding to ankyrin-G mutants R13, R14, and R15 ( Fig. 7, D and E ). In fact, GFP -ankyrin-G mutants R14 and R15 displayed a near complete loss of Na v 1.5 DII -DIII binding activity in these assays. Together, our fi ndings demonstrate that ankyrin-GNav1.5 binding is exclusively dependent on three critical elements (two ␤ -hairpin loops on ankyrin-G and a nine -amino acid motif on Na v 1.5; Mohler et al., 2004b ) .
Human ankyrin-G expression rescues abnormal Nav1.5 localization
We performed rescue assays to determine whether the loss of Na v 1.5 localization in cardiomyocytes with reduced ankyrin-G ex pression was specifi cally caused by the monogenic loss of ankyrin-G. Rat neonatal cardiomyocytes with reduced levels of ankyrin-G and Na v 1.5 (as a result of the presence of rat-specifi c ankyrin-G shRNA virus) were transfected with cDNA encoding human GFP -ankyrin-G. This GFP -ankyrin-G cDNA is resistant to the rat ankyrin-G shRNA ( Fig. 1 ) . As expected, shRNA-transduced cardiomyocytes displayed decreased expression and abnormal localization of Na v 1.5 ( Fig. 8 B ) . In contrast, shRNA-transduced cardiomyocytes expressing human GFP -ankyrin-G cDNA displayed a Na v 1.5 distribution similar to wild-type cardiomyocytes ( Fig. 8 C ) . These data demonstrate that abnormal Na v 1.5 localization in ankyrin-G -null cardiomyocytes can be rescued by the exogenous expression of human ankyrin-G and reinforce the critical role for ankyrin-G in the subcellular localization of Na v 1.5 in cardiomyocytes.
Direct ankyrin-G -Na v 1.5 interaction is required for Na v 1.5 localization
We used the aforementioned ankyrin-G rescue assay with ankyrin-G mutants that lack Na v 1.5-binding activity ( Fig. 7 ) to determine whether direct ankyrin-G -Na v 1.5 interactions are required for Na v 1.5 localization in cardiomyocytes. Ankyrin-G mutants lacking Na v 1.5-binding activity were introduced into full-length human GFP -ankyrin-G cDNA to create human GFP -ankyrin-G R14 and R15 (both resistant to rat ankyrin-G shRNA). Cardiomyocytes with reduced ankyrin-G expression (transduced with rat ankyrin-G YFP virus) were transfected with human GFP -ankyrin-G or human ankyrin-G R14 or R15 mutant cDNAs. YFP-positive cardiomyocytes (express shRNA) were fixed and immunostained. GFP -ankyrin-G is properly targeted in neonatal cardiomyocytes and rescues the normal expression of Na v 1.5 ( Fig. 8 C ) . In contrast, although both GFP -ankyrin-G R14 and GFP -ankyrin-G R15 were properly localized in transfected cardiomyocytes, there was no detectable rescue of Na v 1.5 localization as observed with wild-type human GFP -ankyrin-G ( Fig. 8 C ) . In fact, the localization of Na v 1.5 in myocytes transfected with GFP -ankyrin-G R14 -15 was similar to nontransfected myocytes lacking endogenous ankyrin-G expression ( Fig. 8, B, D , and E ). Therefore, direct association of ankyrin-G with Na v 1.5 is required for the membrane expression of Na v 1.5 in ventricular cardiomyocytes. Figure 6 . Reduced ankyrin-G expression does not affect Na v 1.5 inactivation in primary cardiomyocytes. Superimposed Na v 1.5 inactivation curves obtained from neonatal rat cardiomyocytes treated with control (black squares) and species-specifi c (human, gray circles; rat, white squares) ankyrin-G shRNA viruses. The normalized I Na plotted against preconditioning pulse potential was fi tted using a Boltzmann equation. Voltage-dependent steady-state inactivation was determined using a paired two-pulse protocol. Each conditioning voltage is paired with a control after 1.5 s. A 500-ms conditioning pulse from Ϫ 120 to 20 mV in 10-mV increments was followed by a test pulse to Ϫ 30 mV. The test pulse in each series is separated from the conditioning pulse by a 2-ms interval to Ϫ 120 mV. Each point (I Na ) is normalized against the amplitude of corresponding control pulse (I Namax ). Each point represents mean ± SEM (error bars; n = 5).
strate that direct interaction of the ankyrin-G membrane -binding domain and Na v 1.5 DII -DIII loop is necessary for Na v 1.5 expression and localization at the cardiomyocyte membrane surface. Our new data provide compelling evidence that ankyrin-Gdependent targeting of Na v 1.5 is a fundamental requirement for cardiomyocytes and likely other excitable cells.
Ankyrin polypeptides have likely coordinately evolved to regulate electrical activity in the heart by targeting key ion channels/transporters involved in controlling the cardiac action potential. Ankyrin-G directly associates with and targets Na v 1.5 to the membrane surface ( Fig. 9 A ) to regulate inward Na + current and, thus, action potential initiation and cardiomyocyte depolarization. Therefore, it is not surprising that human SCN5A variants that disrupt ankyrin-G interactions are associated with the Brugada Syndrome ( Priori et al., 2002; Mohler et al., 2004b ) , a cardiac syndrome associated with reduced inward I Na (for review see Napolitano and Priori, 2006 ) . Clinical features of the Brugada Syndrome include fast polymorphic ventricular tachycardia typically occurring at rest or during sleep ( Wilde and Priori, 2000 ) . In contrast, ankyrin-B targets distinct ion channels and transporters with central roles in cytosolic calcium extrusion during cardiac repolarization ( Mohler et al., 2002 ( Mohler et al., , 2003 ( Mohler et al., , 2004c ( Mohler et al., , 2005 Cunha et al., 2007 ) . Ankyrin-B (product of the ANK2 gene) is required for targeting Na/Ca exchanger, Na/K ATPase, and InsP 3 receptor to the transverse tubule and
Ankyrin-G is required for normal Na v 1.5 expression in adult cardiomyocytes
To test whether our fi ndings in neonatal myocytes can also be applied to adult cardiomyocytes, we performed ankyrin-G shRNA viral transduction of freshly isolated adult rat cardiomyocytes. Na v 1.5 expression is most pronounced at the intercalated disc of adult cardiomyocytes (see Na v 1.5 localization in the control myocyte; Fig. S2 A, available at http://www.jcb.org/cgi/content/ full/jcb.200710107/DC1). Therefore, we tested whether ankyrin-G expression is required for Na v 1.5 localization at the mature cardiomyocyte intercalated disc. Reduced ankyrin-G expression in adult myocytes results in the reduced membrane expression of Na v 1.5 (note the loss of Na v 1.5 intercalated disc staining in Fig.  S2 B) , which is consistent with results in neonatal cardiomyocytes. In fact, identical with our fi ndings in neonatal cells, we observed that Na v 1.5 localized to the perinuclear region (Fig. S2 B) in adult cardiomyocytes with reduced ankyrin-G expression. These data from isolated adult cardiomyocytes further confi rm the role of the ankyrin-G -based protein-targeting pathway for Na v 1.5 membrane expression in the heart.
Discussion
In this study, we present the fi rst report of a cellular pathway required for Na v channel traffi cking in cardiomyocytes. We demon- ankyrin-B for both integral membrane and signaling proteins in the heart suggests that the ankyrin-G -targeting pathway may similarly facilitate the localization of additional myocyte proteins. Moreover, our new fi ndings for ankyrin-G in Na v 1.5 targeting identify an attractive, unconventional candidate disease gene for cardiac (arrhythmia and myopathy) and other excitable cell diseases.
Based on the role of ankyrin-R in the erythrocyte ( Bennett and Stenbuck, 1979 ) , cardiac ankyrin-G may simply act as a membrane scaffold to link integral membrane proteins (such as Na v 1.5) with the underlying actin-and spectrin-based cytoskeleton. In support of this role, we observe a signifi cant level of Na v 1.5 clustering on the plasma membrane surface with ankyrin-G as assessed by immunoelectron microscopy of cardiomyocyte membrane sheets ( Fig. 10 ) . Alternatively, ankyrin-G may play an active role in the cellular traffi cking of Na v 1.5 to specifi c membrane domains. In theory, ankyrin-G could have multiple sarcoplasmic reticulum in cardiomyocytes ( Fig. 9 B ; Mohler et al., 2003 Mohler et al., , 2005 .
Dysfunction in ankyrin-B -based cellular pathways as a result of human ANK2 variants are associated with ankyrin-B syndrome, a cardiac arrhythmia with a host of phenotypes, including sinoatrial node dysfunction, atrial fi brillation, conduction defects, and ventricular tachycardia and/or sudden cardiac death ( Mohler et al., 2003 ( Mohler et al., , 2004c . In contrast to Na v 1.5-associated Brugada Syndrome, ventricular tachycardia and syncopal events in the ankyrin-B syndrome are most often associated with adrenergic stimulation (e.g., emotional stress and/or exercise, similar to catecholaminergic polymorphic arrhythmia; Mohler et al., 2003 Mohler et al., , 2004c Mohler et al., , 2007 Liu et al., 2007 ) .
In addition to targeting ion channels in cardiomyocytes, ankyrin-B was recently shown to be required for targeting of the regulatory subunit of the PP2A complex in primary cardiomyocytes ( Fig. 9 B ; Bhasin et al., 2007 ) . This broad targeting role of Figure 8 . Na v 1.5 targeting requires direct interaction with 190-kD ankyrin-G. (A and B) Immunolocalization of ankyrin-G and Na v 1.5 in control (nontransduced) and rat ankyrin-G shRNA virally transduced neonatal cardiomyocytes. Note the localization of Na v 1.5 in the perinuclear region of shRNA-transduced myocytes (white arrows). Yellow arrows denote remaining ankyrin-G staining in transduced myocytes, and asterisks mark sites of complete knockdown. Virally transduced myocytes in the fi gure are denoted by positive YFP fl uorescence (pseudocolored in blue). (C) Cardiomyocytes expressing rat-specifi c ankyrin-G shRNA (note the blue color denoting YFP expression) were transfected with GFP-labeled human ankyrin-G cDNA and immunolabeled with Na v 1.5 and ankyrin-G antibodies. Note that human GFPankyrin-G restores the localization of Na v 1.5 to normal (compare Na v 1.5 in B and C). (D and E) GFP-human ankyrin-G mutants (R14 and R15) that lack binding activity for Na v 1.5 (see Fig. 6 ) are unable to rescue to normal the aberrant localization of Na v 1.5 (note perinuclear distribution; arrows) in myocytes stably transduced with rat ankyrin-G shRNA (note positive YFP fl uorescence). Bars, 10 m.
These fi ndings are in contrast to a recent publication that demonstrated abnormal inactivation gating of Na v 1.2 in TsA201 cells (modifi ed HEK293 cell) lacking ankyrin-G ( Shirahata et al., 2006 ) . Our new data suggest that these measurements should be reevaluated in the context of a neuron.
The critical role of ion channels and transporters for normal cardiac function has been highlighted by the linkage of gene mutations in cardiac ion channels and associated subunits with human arrhythmia ( Lehnart et al., 2007 ) . Specifi cally, human gene variants in KCNQ1 (KvLQT1), KCNH2 (HERG), SCN5A (Nav1.5), KCNE1 (minK), KCNE2 (MiRP), KCNJ2 (Kir2.1), and CACNA1C (Cav1.2) have been associated with potentially fatal long QT arrhythmias ( Lehnart et al., 2007 ) . Most channel variants affect channel biophysics ( Lehnart et al., 2007 ) . However, recent fi ndings suggest that dysfunction in channel traffi cking mechanisms may explain a signifi cant number of long QT variant cellular phenotypes ( Zhou et al., 1999; Mohler et al., 2003 ; Ye et al., 2003 ; Gouas et al., 2004 ; Krumerman et al., 2004 ; Liu et al., 2005 ; Anderson et al., 2006 ; Ballester et al., 2006; Schmitt et al., 2007 ) .
Cardiomyocytes have clearly evolved unique channel traffi cking pathways for the precise localization of specifi c ion channels to unique cardiomyocyte membrane domains. For example, although Na v 1.5, K v 4.2, and connexin 43 are concentrated at the intercalated disc ( Kanter et al., 1992 ; Barry et al., 1995 ; Maier et al., 2002 ; Mohler et al., 2004b ) , Kir2.1, Kir2.3, and Ca v 1.2 are primarily localized to transverse tubule membranes ( Carl et al., 1995 ; Sun et al., 1995; Clark et al., 2001 ; Melnyk et al., 2002 ) . Moreover, signifi cant populations of Kv-LQT1, ERG, minK, MiRP, Na/Ca exchanger, and Na/K ATPase are found at transverse tubule and peripheral sarcolemma membranes ( Frank et al., 1992 ; Kieval et al., 1992 ; McDonough et al., 1996 ; Pond et al., 2000 ; Rasmussen et al., 2004 ; Wu et al., 2006 ) . Finally, high resolution imaging techniques have revealed unique roles in both traffi cking and stabilization/retention of Na v 1.5 channels in the heart. Although these fi ndings are beyond the scope of this study, elucidating the specifi c cellular roles of ankyrin polypeptides in excitable cells is an obvious future goal for the fi eld.
Reduction of ankyrin-G in cardiomyocytes signifi cantly affects the expression ( > 75%; Fig. 2 ) and cellular localization of Na v 1.5 ( Fig. 3 ) . Although functional experiments on ankyrin-G shRNA myocytes reveal a striking reduction in I Na (50 -65% reduction), residual I Na current was observed in these cells ( Fig. 5 ) . This current may represent residual Na v 1.5 activity. Alternatively, this remaining current may refl ect the combined activity of other Na v isoforms ( Rogart et al., 1989; Baruscotti et al., 1997 ; Dhar Malhotra et al., 2001 ; Maier et al., 2002 Maier et al., , 2003 Maier et al., , 2004 Haufe et al., 2005 ) . In theory, these Na v channel isoforms may be targeted to the membrane via an ankyrin-G -independent cellular pathway and, therefore, may be resistant to ankyrin-G knockdown. These interesting data form the foundation for future experiments to dissect the specificity of the ankyrin-Gbased cellular pathway for Na v channel isoform traffi cking in the heart.
Our electrophysiological measurements illustrate the importance of studying ankyrin -membrane protein interactions in the physiological context of a native cell. Our previous work suggested that Na v 1.5 E1053K lacking ankyrin-G -binding activity displayed minor yet signifi cant abnormalities in activation and inactivation when expressed in HEK293 cells ( Mohler et al., 2004b ) . However, when expressed in native cardiomyocytes, these biophysical abnormalities were inconsequential, as the majority of the channel lacked suffi cient targeting information to even reach the plasma membrane ( Mohler et al., 2004b ) . Our new fi ndings demonstrate that in myocytes lacking ankyrin-G, the small number of residual Na v 1.5 channels that reach the plasma membrane have effectively normal biophysical characteristics. Figure 9 . Ankyrin-G and ankyrin-B ion channel/transporter complexes in the heart. (A) Ankyrin-G is required for the targeting of Na v 1.5 to the cardiomyocyte intercalated disc. Although other Na v 1.5-interacting proteins have been identifi ed, it is not yet clear whether these are present in the ankyrin-Gdependent protein complex. (B) Ankyrin-B is required for the targeting of Na/Ca exchanger and Na/K ATPase to transverse tubule membranes in the heart. InsP 3 receptor targeting to the sarcoplasmic reticulum membrane requires direct interaction with ankyrin-B. Cardiac ankyrin-B protein partners also include PP2A and ␤ 2-spectrin.
fi rst component of a larger ankyrin-G macromolecular signaling complex at cardiomyocyte excitable membrane domains.
Materials and methods
shRNA targets/cDNA constructs Ankyrin-G -specifi c shRNA targets were selected based on their unique sequence presence of fl anking 5 Ј AA and 3 Ј TT nucleotides ( Brummelkamp et al., 2002 ) . Human-and rat-specifi c targets were conferred by three unique nucleotides located at wobble positions. Primers were created and ligated into a modifi ed pFIV lentiviral vector (System Biosciences, Inc.). The vector was modifi ed to contain YFP driven by an independent H1PGK promoter to track transduced cells. Feline immunodefi ciency viruses were titered before transduction experiments. Ankyrin-G constructs were generated using 190-kD ankyrin-G cDNA. GFP 190-kD ankyrin-G mutant constructs were made using QuikChange Mutagenesis (Stratagene). Loop mutations were designed to replace ANK repeat ␤ -hairpin loop tip residues with two alanines. Rescue constructs were made using GFP 190-kD ankyrin-G and ANK repeat mutants R14 and R15. All constructs were completely sequenced and confi rmed to express protein in HEK293 cells.
Immunoblots
After viral and/or rescue treatment, cells were collected into PBS, pH 7.4. Cells were lysed using radioimmunoprecipitation assay buffer containing protease inhibitor cocktail. Detergent-soluble fractions were collected after high speed centrifugation, and protein concentrations were determined using a bicinchoninic acid protein assay kit (Thermo Fisher Scientifi c). Equal quantities of protein (20 μ g) were analyzed by SDS-PAGE and immunoblotting. Equal loading was assessed by transfer to Ponceau S and blotting with NHERF1.
Neonatal rat cardiomyocytes
Hearts were dissected from postnatal day 1 rats and cultured as described previously .
Adult cardiomyocytes
Myocytes were isolated from 250 -300 g of Sprague-Dawley rats ( Grueter et al., 2006 ). Acutely isolated cardiomyocytes were then plated at high density ( ‫ف‬ 2 × 10 6 per well), infected with rat-specifi c ankyrin-G shRNA virus or control virus for 9 h, and maintained for 22 h at 37 ° C before experiments.
Binding experiments GFP 190-kD ankyrin-G and mutants were expressed in HEK293 cells and purified using affinity-purified GFP Ig coupled to protein A agarose beads. Cells were lysed in homogenization buffer plus 1.0% Triton X-100 and 0.5% deoxycholate ( Mohler et al., 2005 ) . The extract was transverse tubule membrane domains that further segregate cardiac ion channel signaling complexes ( Scriven et al., 2000 ) . Clearly, the molecular and structural characteristics of cardiac membrane domains represent a central feature for the regulation of local ion channel pathways and represent a relatively unexplored fi eld in cell biology.
Ankyrin-based ion channel traffi cking pathways have unique roles in specifi c cells. Recently, Pan et al. ( 2006 ) demonstrated the requirement of ankyrin-G association for the targeting of KCNQ2 and KCNQ3 (encode axonal M currents responsible for stabilizing neuronal resting potential) to axon initial segments. Specifically, ankyrin-G cerebellar-specific null mice display loss of KCNQ2/3 clustering at axonal initial segments ( Pan et al., 2006 ) . Moreover, the ankyrin-G -binding motif originally described in Na v 1.2 and Na v 1.5 ( Garrido et al., 2003 ; Lemaillet et al., 2003 ; Mohler et al., 2004b ) is present in the C-terminal domain of KCNQ2/3 and is required for neuronal KCNQ2/3 targeting ( Chung et al., 2006 ; Pan et al., 2006 ; Rasmussen et al., 2007 ) . Interestingly, although nearly structurally identical, KCNQ1 (cardiac KvLQT1) lacks the C-terminal ankyrin-G -binding motif ( Pan et al., 2006 ) . Consistent with this data, ankyrin-G and KCNQ1 are differentially targeted in ventricular cardiomyocytes ( Mohler et al., 2004b ; Rasmussen et al., 2004 ) . Therefore, these data strongly suggest that ankyrin-based pathways operate in a cell type -specifi c manner.
In summary, our new findings show that ankyrin-G is the physiological binding partner for Na v 1.5 in cardiomyocytes. Loss of direct interaction between ankyrin-G and Na v 1.5 results in abnormal Na v 1.5 channel localization in primary cardiomyocytes. Moreover, the loss of ankyrin-G expression affects Na v 1.5 expression, membrane localization, and, therefore, whole cell Na v 1.5 activity. Based on recent ankyrin fi ndings in the brain ( Dubreuil, 2006 ; Pan et al., 2006 ; Yang et al., 2007 ) , heart ( Lencesova et al., 2004 ; Mohler and Bennett, 2005a ) , and skeletal muscle ( Bagnato et al., 2003 ; Kontrogianni-Konstantopoulos et al., 2004 , 2006 , our new fi ndings likely represent only the Figure 10 . Na v 1.5 is clustered at the cardiomyocyte membrane surface with ankyrin-G. Immunogold electron microscopy of adult rat ventricular cardiomyocyte plasma membrane sheets. Anti -ankyrin-G Ig particles (10 nm gold) and anti-Na v 1.5 Ig particles (5 nm gold; arrows) are found in clusters at the plasma membrane. The majority of Na v 1.5-positive gold particles were clustered in proximity ( < 10 nm) to ankyrin-G -positive gold particles (see A, B, and D -F). However, we also observed a small fraction of Na v 1.5-positive particles that were physically isolated from ankyrin-G (C). Membrane sheets labeled with gold-conjugated secondary antibodies (negative control) were clear of any gold particles (not depicted). Bar, 50 nm. compensated value. The whole-cell bath solution contained 10 mM NaCl, 130 mM choline chloride, 4.5 mM KCl, 1.8 mM CaCl 2 , 2.0 mM MgCl 2 , 10.0 mM Hepes, and 5.5 mM glucose, pH 7.35, titrated with KOH. The pipette solution contained 130 mM CsCl, 0.5 mM CaCl 2 , 2 mM MgCl 2 , 5 mM Na 2 ATP, 0.5 mM GTP, 5 mM EGTA, and 10 mM Hepes, pH 7.3, titrated with CsOH. All electrophysiology experiments were performed at room temperature (21 -23 ° C).
Whole-cell voltage clamp Na + current data were elicited from a holding potential of Ϫ 120 mV to membrane potentials ranging from Ϫ 110 to 30 mV in the presence of 2.0 mM CoCl 2 . Voltage-dependent steadystate inactivation was determined using a paired two-pulse protocol. Each conditioning voltage was paired with a control after 1.5 s. A 500-ms conditioning pulse from Ϫ 120 to 20 mV in 10-mV increments was followed by a test pulse to Ϫ 30 mV. The test pulse in each series was separated form the conditioning pulse by a 2-ms interval to Ϫ 120 mV. The steady-state inactivation curves were constructed by normalizing currents to the maximal Na + current elicited from a holding potential of Ϫ 120 to Ϫ 30 mV for a duration of 20 ms. The resulting curve was fi tted using a Boltzmann distribution equation of the form I Na = I Na, max /(1 + exp([V m Ϫ V 1/2 ]/k)), where V m is the conditioning pulse voltage, V 1/2 is the voltage at half-inactivation, and k is the slope factor. The whole-cell voltage clamp protocol showing I Na and I Ca in Fig. 5 F was elicited using the two-pulse paradigm shown in Fig.  5 G . From a holding potential of Ϫ 100 mV, I Na was elicited by a 30-ms pulse to Ϫ 30 mV. The membrane potential was then hyperpolarized to Ϫ 70 mV for 10 ms. I Ca was then elicited by a 50-ms pulse to 0 mV. This protocol allowed the simple differentiation of I Na from I Ca as indicated by the unique I Ca and I Na current signatures in Fig. 5 . All presented currents were normalized for cell capacitance. Data were collected and analyzed using pCLAMP 9.0 software (MDS Analytical Technologies) and OriginPro 7.5 (OriginLab Corp.). Analysis of variance was used to compare the nominal change in current density among the means. Statistical significance is defi ned as P < 0.05. Fig. S1 demonstrates that cardiomyocytes with reduced ankyrin-G expression display normal localization and distribution of Cav1.2 and Na/ Ca exchanger. Fig. S2 demonstrates that a full complement of ankyrin-G expression is required for normal Nav1.5 expression in adult rat cardiomyocytes. Online supplemental material is available at http://www.jcb .org/cgi/content/full/jcb.200710107/DC1. centrifuged at 100,000 g , and the supernatant was incubated with GFP Ig coupled to protein A -Sepharose. Na v 1.5 DII -DIII cytoplasmic loop was subcloned into pET15b for expression and purifi cation as a hexahistidine fusion protein. Purifi ed proteins were incubated with GFP or control Ig coupled to protein A -Sepharose. Protein bound to each mutant GFP 190-kD ankyrin-G was eluted, analyzed by immunoblotting, normalized for relative GFP ankyrin-G expression, and compared with wild-type GFP 190-kD ankyrin-G binding.
Online supplemental material
Statistics
When appropriate, data were analyzed using a two-tailed t test, and P < 0.05 was considered signifi cant. Values are expressed as the mean ± SD.
Virus generation
Ankyrin-G shRNAs were engineered into the pFIV lentiviral vector and packaged into viral pseudoparticles (System Biosciences, Inc.). Constructs were cotransfected with packaging plasmids into HEK293 cells using Effectene. The pseudoparticle-containing supernatant was concentrated using Centriplus YM-30 columns. The concentrate was stored at Ϫ 80 ° C.
Immunostaining/confocal microscopy Cardiomyocytes were isolated, cultured, and processed for immunofl uorescence as described previously ( Mohler et al., 2003; Cunha et al., 2007 ) . Secondary antibodies included anti -rabbit and anti -mouse Igs conjugated to AlexaFluor488 or 568 (Invitrogen). Phalloidin-conjugated AlexaFluor633 was used for double-labeling experiments in Fig. S1 . After secondary antibody treatment, cells were extensively washed, covered with Vectashield imaging medium (Vector Laboratories), and coverslips (#1) were applied. Images were collected on a confocal microscope (510 Meta; Carl Zeiss, Inc.) with a 63 × oil 1.40 NA or 40 × oil 1.30 NA lens (pinhole equals 1.0 airy disc; Carl Zeiss, Inc.) using imaging software (release version 4.0 SP1; Carl Zeiss, Inc.). Images were collected using similar confocal protocols at room temperature. In experiments in which both AlexaFluor488 and YFP were analyzed, the emission signal from AlexaFluor488 was collected from 500 to 515 nm, and the emission from YFP was collected from 530 to 565 nm. Because YFP was only used to identify virus-positive cells (versus identifying the localization of a YFP fusion protein), we used minimal laser power and detector gain (thus the minimal YFP image resolution) to collect YFP images to prevent potential signal bleedthrough to the AlexaFluor488 image, in which protein immunolocalization was crucial. For images in Figs. 3, 8 , and S1, the YFP image was pseudocolored. Images were imported into Photoshop CS (Adobe) for cropping and linear contrast adjustment.
Plasma membrane sheet preparation/immunoelectron microscopy Ventricular cardiac myocytes from adult Sprague-Dawley rats were obtained as described previously ( Shibata et al., 2006 ) . Immunolabeling of the membrane sheets was performed by placing the grids on drops of primary antibody solution for 1 h on ice and rinsing six times for 5 min in PBS containing BSA. Grids were then incubated on drops of gold-conjugated secondary antibody solution (5 nm of goat anti -rabbit diluted 1:50 or 10 nm of goat anti -mouse diluted 1:50 in PBS containing BSA; Electron Microscopy Sciences) for 1 h on ice. Grids were then rinsed three times for 5 min in PBS containing BSA followed by a 2-min fi xation in 2.5% glutaraldehyde. Finally, the grids were washed for 5 min in deionized water before being allowed to air dry. Negative controls included grids labeled with secondary antibody alone. Grids were visualized on a transmission electron microscope (H-70000; Hitachi).
Antibodies
Antibodies used include anti-Na v 1.5 (Alomone Laboratories), anti-NCX1 (Swant), anti -connexin43 (Invitrogen), anti-Ca v 1.2 (Affi nity BioReagents), anti-NHERF1 (Sigma-Aldrich), affi nity-purifi ed Igs against ankyrin-B, ankyrin-G, and GFP (monoclonal and polyclonal), and goat anti -rabbit AlexaFluor568 (Invitrogen).
Electrophysiology experiments
Voltage-dependent Na + and Ca +2 currents were measured using standard patch clamp techniques. Whole-cell currents were recorded with an amplifi er (Axopatch 200B; MDS Analytical Technologies), and the analogue signal was fi ltered using an eight-pole fi lter (Bessel) with a bandwidth of 5 kHz and was digitized at a sampling rate of 50 kHz. Borosilicate glass capillaries (VWR Scientifi c) were used to fabricate patch pipettes. Electrode resistances ranged from 1 to 1.5 M Ω , and seal resistances were 1 -5 G Ω . Pipette seal resistances were compensated to > 85% of the un-
